Clinical Trial Update: Natalizumab in Inclusion Body Myositis (IBM) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating natalizumab for inclusion body myositis is ongoing, with the current status listed as unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inclusion Body Myositis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Phoenix Neurological Associates, LTD | Conditions: Inclusion Body Myositis (IBM) | Phase 1 | Status: UNKNOWN